Arcadia Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcadia Biosciences, Inc. (Nasdaq: RKDA) on August 7, 2024, covering events occurring on August 1, 2024. The filing addresses corporate governance changes regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters.
Material Changes
- Board Appointment: On August 1, 2024, the Board appointed Thomas J. Schaefer, the Company's current President and Chief Executive Officer, as a Class I director.
- Board Vacancy: The appointment fills a vacancy created by the resignation of Stanley Jacot, effective July 2, 2024.
- Executive Background: Mr. Schaefer has served as CEO since July 5, 2022, and as CFO since January 2023. He joined Arcadia in July 2020 and holds a CFA designation.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirm the effective date of Stanley Jacot's resignation (July 2, 2024) and the subsequent appointment of Thomas J. Schaefer (August 1, 2024).
- Verify Mr. Schaefer's dual role as both CEO and a Class I director.
- Review the Company's most recent 10-Q or 10-K for financial performance data, as this 8-K contains no financial metrics.